Prevention and treatment of bronchopulmonary dysplasia: Current status and future prospects

Journal of Perinatology

Volumn 27, Issue , 2007, Pages S26-S32

  Thomas, W ^a   Speer, C P ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

Anti oxidants; Bronchopulmonary dysplasia; Oxygen; Prematurity; Prevention; Treatment

Indexed keywords

ACETYLCYSTEINE; ALPHA1 PROTEINASE INHIBITOR III; CAFFEINE; CLARA CELL PROTEIN; CORTICOSTEROID; DIURETIC AGENT; ERYTHROMYCIN; GLUTATHIONE; METHYLXANTHINE DERIVATIVE; NITRIC OXIDE; OXYGEN; PLACEBO; PORACTANT; RETINOL; SUPEROXIDE DISMUTASE; SURFACTANT;

ANTIINFLAMMATORY ACTIVITY; CHILD CARE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; EVIDENCE BASED MEDICINE; HUMAN; LOW BIRTH WEIGHT; LUNG DYSPLASIA; LUNG FUNCTION; NEWBORN; OXYGEN THERAPY; PATHOGENESIS; PROPHYLAXIS; REVIEW; RISK REDUCTION; TREATMENT OUTCOME; UREAPLASMA UREALYTICUM;

EID: 34247524089     PISSN: 07438346     EISSN: 14765543     Source Type: Journal    
DOI: 10.1038/sj.jp.7211723     Document Type: Article

References (65)

1. Jobe AH, Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med 2001; 163: 1723–1729.
2. Speer CP. Inflammation and bronchopulmonary dysplasia: A continuing story. Semin Fetal Neonatal Med 2006; 11: 354–362.
3. Speer CP. Pulmonary inflammation and bronchopulmonary dysplasia. J Perinatol 2006; 26: S57–S62.
4. Van Marter LJ. Progress in discovery and evaluation of treatments to prevent bronchopulmonary dysplasia. Biol Neonate 2006; 89: 303–312.
5. Thomas W, Speer CP. Management of infants with bronchopulmonary dysplasia in Germany. Early Hum Dev 2005; 81: 155–163.
6. Saugstad OD. Chronic lung disease: Oxygen dogma revisited. Acta Paediatr 2001; 90: 113–115.
7. Saugstad OD, Ramji S, Vento M. Resuscitation of depressed newborn infants with ambient air or pure oxygen: A meta-analysis. Biol Neonate 2005; 87: 27–34.
8. Lundstrom KE, Pryds O, Greisen G. Oxygen at birth and prolonged cerebral vasoconstriction in preterm infants. Arch Dis Child Fetal Neonatal Ed 1995; 73: F81–F86.
9. Tin W, Milligan DW, Pennefather P, Hey E. Pulse oximetry, severe retinopathy, and outcome at one year in babies of less than 28 weeks gestation. Arch Dis Child Fetal Neonatal Ed 2001; 84: F106–F110.
10. The STOP-ROP Multicenter Study Group. Supplemental Therapeutic Oxygen for Prethreshold Retinopathy Of Prematurity (STOP-ROP), a randomized, controlled trial. I: Primary outcomes. Pediatrics 2000; 105: 295–310.
11. Askie LM, Henderson-Smart DJ, Irwig L, Simpson JM. Oxygen-saturation targets and outcomes in extremely preterm infants. N Engl J Med 2003; 349: 959–967.
12. Coalson JJ. Pathology of chronic lung disease of early infancy. In: Bland RD, Coalson JJ (eds). Chronic Lung Disease in Early Infancy. Marcel Dekker: New York, 2000, pp 85–124.
13. The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in full-term nearly full-term infants with hypoxic respiratory failure. N Engl J Med 1997; 336: 597–604.
14. Hascoet JM, Fresson J, Claris O, Hamon I, Lombet J, Liska A et al. The safety and efficacy of nitric oxide therapy in premature infants. J Pediatr 2005; 146: 318–323.
15. Kinsella JP, Walsh WF, Bose CL, Gerstmann DR, Labella JJ, Sardesai S et al. Inhaled nitric oxide in premature neonates with severe hypoxaemic respiratory failure: A randomised controlled trial. Lancet 1999; 354: 1061–1065.
16. Schreiber MD, Gin-Mestan K, Marks JD, Huo D, Lee G, Srisuparp P. Inhaled nitric oxide in premature infants with the respiratory distress syndrome. N Engl J Med 2003; 349: 2099–2107.
17. Van Meurs KP, Wright LL, Ehrenkranz RA, Lemons JA, Ball MB, Poole WK et al. Inhaled nitric oxide for premature infants with severe respiratory failure. N Engl J Med 2005; 353: 13–22.
18. Ballard RA, Truog WE, Cnaan A, Martin RJ, Ballard PL, Merrill JD et al. Inhaled nitric oxide in preterm infants undergoing mechanical ventilation. N Engl J Med 2006; 355: 343–353.
19. Kinsella JP, Cutter GR, Walsh WF, Gerstmann DR, Bose CL, Hart C et al. Early inhaled nitric oxide therapy in premature newborns with respiratory failure. N Engl J Med 2006; 355: 354–364.
20. Barrington KJ, Finer NN. Inhaled nitric oxide for respiratory failure in preterm infants. Cochrane Database Syst Rev 2006; 1: Doi:10.1002/14651858.CD000509.pub2.
21. Soll RF, Morley CJ. Prophylactic versus selective use of surfactant in preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev 2001; 2: Doi:10.1002/14651858.CD000510.
22. Egberts J, Brand R, Walti H, Bevilacqua G, Breart G, Gardini F. Mortality, severe respiratory distress syndrome, and chronic lung disease of the newborn are reduced more after prophylactic than after therapeutic administration of the surfactant Curosurf. Pediatrics 1997; 100: E4.
23. Brion LP, Primhak RA. Intravenous or enteral loop diuretics for preterm infants with (or developing) chronic lung disease. Cochrane Database Syst Rev 2002; 1: Doi:10.1002/14651858.CD001453.
24. Brion LP, Primhak RA, Ambrosio-Perez I. Diuretics acting on the distal renal tubule for preterm infants with (or developing) chronic lung disease. Cochrane Database Syst Rev 2002; 1: Doi:10.1002/14651858.CD001817.
25. Brion LP, Primhak RA, Yong W. Aerosolized diuretics for preterm infants with (or developing) chronic lung disease. Cochrane Database Syst Rev 2006; 3: Cd001694.
26. Henderson-Smart DJ, Steer P. Methylxanthine treatment for apnea in preterm infants. Cochrane Database Syst Rev 2001; 3: Doi:10.1002/14651858.CD00140.
27. Schmidt B. Methylxanthine therapy for apnea of prematurity: Evaluation of treatment benefits and risks at age 5 years in the international Caffeine for Apnea of Prematurity (CAP) trial. Biol Neonate 2005; 88: 208–213.
28. Schmidt B, Roberts RS, Davis P, Doyle LW, Barrington KJ, Ohlsson A et al. Caffeine therapy for apnea of prematurity. N Engl J Med 2006; 354: 2112–2121.
29. Shenai JP. Vitamin A supplementation in very low birth weight neonates: Rationale and evidence. Pediatrics 1999; 104: 1369–1374.
30. Spears K, Cheney C, Zerzan J. Low plasma retinol concentrations increase the risk of developing bronchopulmonary dysplasia and long-term respiratory disability in very-low-birth-weight infants. Am J Clin Nutr 2004; 80: 1589–1594.
31. Verma RP, McCulloch KM, Worrell L, Vidyasagar D. Vitamin A deficiency and severe bronchopulmonary dysplasia in very low birthweight infants. Am J Perinatol 1996; 13: 389–393.
32. Pearson E, Bose C, Snidow T, Ransom L, Young T, Bose G et al. Trial of vitamin A supplementation in very low birth weight infants at risk for bronchopulmonary dysplasia. J Pediatr 1992; 121: 420–427.
33. Tyson JE, Wright LL, Oh W, Kennedy KA, Mele L, Ehrenkranz RA et al. Vitamin A supplementation for extremely-low-birth-weight infants. National Institute of Child Health and Human Development Neonatal Research Network. N Engl J Med 1999; 340: 1962–1968.
34. Wardle SP, Hughes A, Chen S, Shaw NJ. Randomised controlled trial of oral vitamin A supplementation in preterm infants to prevent chronic lung disease. Arch Dis Child Fetal Neonatal Ed 2001; 84: F9–F13.
35. Darlow BA, Graham PJ. Vitamin A supplementation for preventing morbidity and mortality in very low birthweight infants. Cochrane Database Syst Rev 2002; 4: Doi:10.1002/14651858.CD000501.
36. Ambalavanan N, Wu TJ, Tyson JE, Kennedy KA, Roane C, Carlo WA. A comparison of three vitamin A dosing regimens in extremely-low-birth-weight infants. J Pediatr 2003; 142: 656–661.
37. Ambalavanan N, Kennedy K, Tyson J, Carlo WA. Survey of vitamin A supplementation for extremely-low-birth-weight infants: Is clinical practice consistent with the evidence? J Pediatr 2004; 145: 304–307.
38. Urlichs F, Speer CP. Neutrophil function in preterm and term infants. NeoReviews 2004; 10: E417–e429.
39. Saugstad OD. Oxidative stress in the newborn – a 30-year perspective. Biol Neonate 2005; 88: 228–236.
40. Gerber CE, Bruchelt G, Stegmann H, Schweinsberg F, Speer CP. Presence of bleomycin-detectable free iron in the alveolar system of preterm infants. Biochem Biophys Res Commun 1999; 257: 218–222.
41. Ahola T, Lapatto R, Raivio KO, Selander B, Stigson L, Jonsson B et al. N-acetylcysteine does not prevent bronchopulmonary dysplasia in immature infants: A randomized controlled trial. J Pediatr 2003; 143: 713–719.
42. Sandberg K, Fellman V, Stigson L, Thiringer K, Hjalmarson O. N-acetylcysteine administration during the first week of life does not improve lung function in extremely low birth weight infants. Biol Neonate 2004; 86: 275–279.
43. Rosenfeld W, Evans H, Concepcion L, Jhaveri R, Schaeffer H, Friedman A. Prevention of bronchopulmonary dysplasia by administration of bovine superoxide dismutase in preterm infants with respiratory distress syndrome. J Pediatr 1984; 105: 781–785.
44. Davis JM, Rosenfeld WN, Richter SE, Parad MR, Gewolb IH, Spitzer AR et al. Safety and pharmacokinetics of multiple doses of recombinant human CuZn superoxide dismutase administered intratracheally to premature neonates with respiratory distress syndrome. Pediatrics 1997; 100: 24–30.
45. Davis JM, Parad RB, Michele T, Allred E, Price A, Rosenfeld W. Pulmonary outcome at 1 year corrected age in premature infants treated at birth with recombinant human CuZn superoxide dismutase. Pediatrics 2003; 111: 469–476.
46. Speer CP, Ruess D, Harms K, Herting E, Gefeller O. Neutrophil elastase and acute pulmonary damage in neonates with severe respiratory distress syndrome. Pediatrics 1993; 91: 794–799.
47. Speer CP. New insights into the pathogenesis of pulmonary inflammation in preterm infants. Biol Neonate 2001; 79: 205–209.
48. Dunn MS, Stiskal JA, O’Brien KK, Ito S, Cox DW, Kelly EN. Alpha-1 proteinase inhibitor (A1PI) therapy for the prevention of chronic lung disease of prematurity (CLD) – a dose ranging study an meta analysis with previous randomized clinical trial (RCT). Pediatr Res 2000; 47: 397A.
49. Stiskal JA, Dunn MS, Shennan AT, O’Brien KK, Kelly EN, Koppel RI et al. Alpha1-proteinase inhibitor therapy for the prevention of chronic lung disease of prematurity: A randomized, controlled trial. Pediatrics 1998; 101: 89–94.
50. Shah P, Ohlsson A. Alpha-1 proteinase inhibitor (a1PI) for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev 2001; 3: Doi:10.1002/14651858.CD002775.
51. Shijubo N, Kawabata I, Sato N, Itoh Y. Clinical aspects of Clara cell 10-kDa protein/uteroglobin (secretoglobin 1A1). Curr Pharm Des 2003; 9: 1139–1149.
52. Levine CR, Gewolb IH, Allen K, Welch RW, Melby JM, Pollack S et al. The safety, pharmacokinetics, and anti-inflammatory effects of intratracheal recombinant human Clara cell protein in premature infants with respiratory distress syndrome. Pediatr Res 2005; 58: 15–21.
53. Halliday HL, Ehrenkranz RA, Doyle LW. Early postnatal (<96 h) corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev 2003; 1: Doi:10.1002/14651858.CD001146.
54. Halliday HL, Ehrenkranz RA, Doyle LW. Delayed (>3 weeks) postnatal corticosteroids for chronic lung disease in preterm infants. Cochrane Database Syst Rev 2003; 1: Cd001145.
55. Halliday HL, Ehrenkranz RA, Doyle LW. Moderately early (7–14 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev 2003; 1; doi:10.1002/14651858.CD001144.
56. Shinwell ES. Benefits and risks of dexamethasone and hydrocortisone in the preterm infant. Biol Neonate 2005; 88: 255–256.
57. Shah SS, Ohlsson A, Halliday H, Shah VS. Inhaled versus systemic corticosteroids for the treatment of chronic lung disease in ventilated very low birth weight preterm infants. Cochrane Database Syst Rev 2003; 1: Doi:10.1002/14651858.CD002057.
58. Shah V, Ohlsson A, Halliday HL, Dunn MS. Early administration of inhaled corticosteroids for preventing chronic lung disease in ventilated very low birth weight preterm neonates. Cochrane Database Syst Rev 2000; 1: Doi:10.1002/14651858.CD001969.
59. Watterberg K. Anti-inflammatory therapy in the neonatal intensive care unit: Present and future. Semin Fetal Neonat Med 2006; 27: 396–401.
60. Schelonka RL, Katz B, Waites KB, Benjamin Jr DK. Critical appraisal of the role of Ureaplasma in the development of bronchopulmonary dysplasia with metaanalytic techniques. Pediatr Infect Dis J 2005; 24: 1033–1039.
61. Castro-Alcaraz S, Greenberg EM, Bateman DA, Regan JA. Patterns of colonization with Ureaplasma urealyticum during neonatal intensive care unit hospitalizations of very low birth weight infants and the development of chronic lung disease. Pediatrics 2002; 110: E45.
62. Groneck P, Schmale J, Soditt V, Stutzer H, Götze-Speer B, Speer CP. Bronchoalveolar inflammation following airway infection in preterm infants with chronic lung disease. Pediatr Pulmonol 2001; 31: 331–338.
63. Jonsson B, Rylander M, Faxelius G. Ureaplasma urealyticum, erythromycin and respiratory morbidity in high-risk preterm neonates. Acta Paediatr 1998; 87: 1079–1084.
64. Lyon AJ, McColm J, Middlemist L, Fergusson S, McIntosh N, Ross PW. Randomised trial of erythromycin on the development of chronic lung disease in preterm infants. Arch Dis Child Fetal Neonatal Ed 1998; 78: F10–F14.
65. Mabanta CG, Pryhuber GS, Weinberg GA, Phelps DL. Erythromycin for the prevention of chronic lung disease in intubated preterm infants at risk for, or colonized or infected with Ureaplasma urealyticum. Cochrane Database Syst Rev 2003; 4: Doi:10.1002/14651858.CD003744.